tiprankstipranks
BioAtla, Context Therapeutics enter exclusive license agreement for BA3362
PremiumThe FlyBioAtla, Context Therapeutics enter exclusive license agreement for BA3362
2M ago
Context Therapeutics Bolsters Board with Industry Veterans
Premium
Company Announcements
Context Therapeutics Bolsters Board with Industry Veterans
3M ago
Context Therapeutics appoints Smith, Walker to board of directors
Premium
The Fly
Context Therapeutics appoints Smith, Walker to board of directors
3M ago
Context Therapeutics initiated with an Overweight at Piper Sandler
PremiumThe FlyContext Therapeutics initiated with an Overweight at Piper Sandler
6M ago
Context Therapeutics price target raised to $10 from $4 at Maxim
Premium
The Fly
Context Therapeutics price target raised to $10 from $4 at Maxim
7M ago
Context Therapeutics Secures Funding, Advances Clinical Trials
Premium
Company Announcements
Context Therapeutics Secures Funding, Advances Clinical Trials
7M ago
Context Therapeutics expects cash to fund operations into late 2024
PremiumThe FlyContext Therapeutics expects cash to fund operations into late 2024
8M ago
Context Therapeutics reports 2023 EPS ($1.50) vs. (93c) last year
Premium
The Fly
Context Therapeutics reports 2023 EPS ($1.50) vs. (93c) last year
8M ago
Context Therapeutics, Inc. (CNTX) Q4 Earnings Cheat Sheet
Premium
Pre-Earnings
Context Therapeutics, Inc. (CNTX) Q4 Earnings Cheat Sheet
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100